ArticleJournal of materials chemistry. B2026
Co-delivery of synaptogenic and angiogenic nanoparticles in MAP scaffolds enhances post-stroke synapse formation.
Article in Journal of materials chemistry. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ischemic stroke remains one of the leading causes of long-term disability worldwide, depriving patients of their quality of life and physical independence. The root cause of this loss of motor movement stems from the disruption of neuronal connections in the infarct site. Limited spontaneous neural re-wiring post-stroke does provide limited functional recovery, but more than two thirds of ischemic stroke patients suffer from long-term disability for the remainder of their lives. Here, we explore the co-delivery of synaptogenic proteins with an angiogenic biomaterial to promote synapse formation in a mouse model of ischemic stroke. The angiogenic biomaterial is based on microporous annealed particle (MAP) scaffolds containing previously reported pro-angiogenic clustered vascular endothelial growth factor (CLUVENA) heparin nanoparticles. To this material, pro-synaptogenic protein thrombospondin-1 (TSP-1) was added either in soluble or clustered nanoparticle form. Co-delivery of TSP-1 with CLUVENA within MAP scaffolds led to enhanced synapse formation in and around the infarct, despite a reduction in axonal sprouting when compared to CLUVENA delivery alone. TSP-1 treatment also resulted in increased glial scar thickness and astrocytic coverage in the peri-infarct region, potentially contributing to limited axonal integration. Overall, these findings highlight the capacity of TSP-1 to modulate the synaptic and glial landscape post-stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.